AU2005269820B2 - Methods for diagnosis using anti-cytokine receptor antibodies - Google Patents

Methods for diagnosis using anti-cytokine receptor antibodies Download PDF

Info

Publication number
AU2005269820B2
AU2005269820B2 AU2005269820A AU2005269820A AU2005269820B2 AU 2005269820 B2 AU2005269820 B2 AU 2005269820B2 AU 2005269820 A AU2005269820 A AU 2005269820A AU 2005269820 A AU2005269820 A AU 2005269820A AU 2005269820 B2 AU2005269820 B2 AU 2005269820B2
Authority
AU
Australia
Prior art keywords
antibody
patient
receptor
cancer
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005269820A
Other languages
English (en)
Other versions
AU2005269820A1 (en
Inventor
Deborah Kay Adcock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Early Detection LLC
Original Assignee
Early Detection LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Early Detection LLC filed Critical Early Detection LLC
Publication of AU2005269820A1 publication Critical patent/AU2005269820A1/en
Application granted granted Critical
Publication of AU2005269820B2 publication Critical patent/AU2005269820B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1033—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2005269820A 2004-07-22 2005-07-20 Methods for diagnosis using anti-cytokine receptor antibodies Ceased AU2005269820B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59040004P 2004-07-22 2004-07-22
US60/590,400 2004-07-22
PCT/US2005/025588 WO2006014646A2 (en) 2004-07-22 2005-07-20 Methods for diagnosis using anti-cytokine receptor antibodies

Publications (2)

Publication Number Publication Date
AU2005269820A1 AU2005269820A1 (en) 2006-02-09
AU2005269820B2 true AU2005269820B2 (en) 2009-03-26

Family

ID=35787681

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005269820A Ceased AU2005269820B2 (en) 2004-07-22 2005-07-20 Methods for diagnosis using anti-cytokine receptor antibodies

Country Status (7)

Country Link
US (1) US7727528B2 (enExample)
EP (1) EP1781818B1 (enExample)
JP (1) JP2008507529A (enExample)
AU (1) AU2005269820B2 (enExample)
CA (1) CA2574496C (enExample)
DK (1) DK1781818T3 (enExample)
WO (1) WO2006014646A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315656D0 (en) * 2003-07-03 2003-08-13 Oxonica Ltd Metal oxide formulations
DK2164514T3 (en) * 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
NZ601583A (en) * 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8058204B2 (en) * 2008-10-24 2011-11-15 GM Global Technology Operations LLC Method for generating a shell of noble metal overlaid on a core of non-noble metal, and catalysts made thereby
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
WO2010068686A2 (en) 2008-12-10 2010-06-17 Joslin Diabetes Center, Inc. Methods of diagnosing and predicting renal disease
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2504032A4 (en) 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
US8992908B2 (en) 2010-11-23 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
WO2015112842A1 (en) * 2014-01-24 2015-07-30 Ntercept, Llc Methods and compositions for immune dis-inhibition
CA2962251A1 (en) 2014-10-03 2016-04-07 Ntercept, Llc Compositions and methods for inhibiting the biological activity of soluble biomolecules
CN108135850A (zh) 2015-07-29 2018-06-08 纳米提克斯有限责任公司 用于清除可溶性生物分子的模块化组合物及其相关方法
CA3004830A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
WO2017210360A1 (en) * 2016-05-31 2017-12-07 Cardiovax, Llc Methods for diagnosing and treating systemic lupus erythematosus
US11065345B2 (en) 2017-01-04 2021-07-20 Nanotics, Llc Methods for assembling scavenging particles
WO2026133460A1 (ja) * 2024-12-18 2026-06-25 株式会社Ｉｐｐジャパン 画像診断装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054421A1 (en) * 1999-03-12 2003-03-20 Rosen Craig A. Nucleic acids, proteins, and antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
JPH0630788A (ja) * 1992-07-16 1994-02-08 Otsuka Pharmaceut Co Ltd ヒトインターロイキン−１に対する組換え抗体
US20030138426A1 (en) * 1997-10-21 2003-07-24 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
EP1283722A1 (en) * 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
WO2003048317A2 (en) * 2001-11-30 2003-06-12 Children's Hospital Medical Center Antibodies to magmas and uses thereof
US20040072237A1 (en) * 2001-12-26 2004-04-15 Barry Schweitzer Use of cytokines secreted by dendritic cells
AU2005240082B2 (en) * 2004-04-30 2009-07-23 Innatus Corporation Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054421A1 (en) * 1999-03-12 2003-03-20 Rosen Craig A. Nucleic acids, proteins, and antibodies

Also Published As

Publication number Publication date
CA2574496C (en) 2014-04-22
WO2006014646A2 (en) 2006-02-09
CA2574496A1 (en) 2006-02-09
AU2005269820A1 (en) 2006-02-09
US20060039857A1 (en) 2006-02-23
EP1781818B1 (en) 2017-09-06
JP2008507529A (ja) 2008-03-13
EP1781818A4 (en) 2008-12-03
WO2006014646A3 (en) 2006-05-04
US7727528B2 (en) 2010-06-01
EP1781818A2 (en) 2007-05-09
DK1781818T3 (en) 2017-10-16

Similar Documents

Publication Publication Date Title
US7727528B2 (en) Methods for diagnosis using anti-cytokine receptor antibodies
CN101824090B (zh) 人源化单克隆抗体hPAM4
JP5110768B2 (ja) モノクローナル抗体ｐａｍ４ならびに膵臓癌の診断および治療のためのその使用
JP2866093B2 (ja) 術中および内視鏡検査的な腫瘍検出ならびに治療に用いられる医薬組成物
Colcher et al. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72. 3) in patients with carcinoma
JPH05502236A (ja) 感染性及び炎症性病変の検出及び治療のためのキメラ抗体
Sivolapenko et al. Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody
McKearn Radioimmunodetection of solid tumors. Future horizons and applications for radioimmunotherapy
AU2010297311B2 (en) Selective detection of bone metastases in renal clear cell carcinoma
Nakamura et al. In vivo radiolocalization of antiosteogenic sarcoma monoclonal antibodies in osteogenic sarcoma xenografts
McQuarrie et al. The effects of circulating antigen on the pharmacokinetics and radioimmunoscintigraphic properties of 99m Tc labelled monoclonal antibodies in cancer patients
JP2515357B2 (ja) 炎症の診断方法および治療方法
RU2018115734A (ru) Полипептиды антител и их применение
Quak et al. Current perspectives in the use of monoclonal antibodies for detection and treatment of head and neck tumors
Murray et al. Diagnostic and therapeutic evaluation of an anti-Langerhans cell histiocytosis monoclonal antibody (NA1/34) in a new xenograft model
JP2005512083A (ja) 細胞集団の移動パターンおよび／または分布パターンを分析するための診断薬を製造するためのヒトｃｄ４分子に特異性を有する標識リガンドの使用
Moldofsky et al. Tumor detection using radiolabeled monoclonal antibodies
Goldenberg Immunological approaches for early cancer detection
Švecová et al. Radioiodination of mouse anti-III β-tubulin antibodies and their evaluation with respect to their use as diagnostic agents for peripheral neuropathies
Becker The Choice of the Best Radiopharmaceutical to Image Specific Clinical Situations in Patients with Infection and Inflammation
Kubaštová et al. Radioiodination and biodistribution of the monoclonal antibody TU-20 and its scFv fragment
Narula et al. Coronary Heart Disease/Myocardial Infarction: Noninvasive Localization of Experimental Atherosclerotic Lesions With Mouse/Human Chimeric Z2D3 F (ab') sub 2 Specific for the Proliferating Smooth Muscle Cells of Human Atheroma Imaging With Conventional and Negative Charge-Modified Antibody Fragments
Granowska et al. Radioimmunoscintigraphy in gastroenterology
Shapiro et al. Thyroid and Parathyroid Imaging
IL165752A (en) Chimeric monoclonal antibody pam4, a conjugate comprising it and an antibody comprising the same or fragments thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired